VBI Vaccines Inc

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: -

Employees: -

Market Cap: $1.8M

Website

Clinical Trials

Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults

Phase 1

Completed

Conditions: Cytomegalovirus Infections

Interventions: Drug: VBI-1501A 2.0 μg
Drug: VBI-1501A 0.5 μg
Drug: VBI-1501A 1.0 μg
Drug: VBI-1501 1.0 μg
Drug: Placebo

First Posted Date: 2016-07-11

Last Posted Date: 2020-04-20

Lead Sponsor: VBI Vaccines Inc.

Target Recruit Count: 128

Registration Number: NCT02826798

Locations: 🇨🇦
Canadian Center for Vaccinology; IWK Health Centre, Halifax, Nova Scotia, Canada
🇨🇦
Vaccine Evaluation Center, Vancouver, British Columbia, Canada
🇨🇦
McGill University Health Centre - Vaccine Study, Pierrefonds, Quebec, Canada

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy